Left Ventricular Remodeling of Hypertrophic Cardiomyopathy  Longitudinal Observation in a Rural Community

Kitaoka, Hiroaki; Kubo, Toru; Okawa, Makoto; Hitomi, Nobuhiko; Furuno, Takashi; Doi, Yoshinori

doi:10.1253/circj.70.1543

Cited by 31 publications

(32 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five patients who had prior documented permanent or paroxysmal AF were excluded. Patients with myocardial infarction and/or other significant heart problems, such as severe valvular heart disease, dilated phase HCM (defined as percentage fractional shortening <25% 27,28 ), congenital heart disease, having an accessory pathway and bundlebranch block, were also excluded.…”

mentioning

confidence: 99%

A985G Polymorphism of the Endothelin-2 Gene and Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

Nagai

Ogimoto

Okayama

et al. 2007

Circ J

View full text Add to dashboard Cite

mentioning

confidence: 99%

A985G Polymorphism of the Endothelin-2 Gene and Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

Nagai

Ogimoto

Okayama

et al. 2007

Circ J

View full text Add to dashboard Cite

“…[1][2][3]17,18) Although LV systolic function is supernormal or preserved in most cases of HCM, progression to systolic impairment occurs in about 5-10% of patients when they are followed for a long period. [4][5][6][7][8][9] It is usually associated with LV remodeling with wall thinning and cavity dilatation, resembling the morphologic features of dilated cardiomyopathy (DCM).…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] On the other hand, it is well known that HCM in a subset of patients progresses to ''dilated'' or ''end-stage'' phase characterized by left ventricular (LV) systolic dysfunction, and patients with dilated phase of HCM (D-HCM) have a poor prognosis. [4][5][6][7][8][9][10] However, various treatments such as the use of an implantable cardioverter-defibrillator (ICD) for prevention of sudden cardiac death and several medications and devices for prevention of heart failure are now available even for patients with D-HCM.…”

mentioning

confidence: 99%

Prognostic Significance of Non-Dilated Left Ventricular Size and Mitral Regurgitation in Patients With Dilated Phase of Hypertrophic Cardiomyopathy

et al. 2017

Self Cite

View full text Add to dashboard Cite

SummaryAlthough a subtype of hypertrophic cardiomyopathy (HCM), dilated phase of HCM (D-HCM) characterized by left ventricular (LV) systolic dysfunction, has been reported to have a poor prognosis, some patients with D-HCM survive for a relatively long period. The degree of LV dilatation and functional mitral regurgitation (MR) are generally thought to be important predictors of poor prognosis in patients with LV systolic dysfunction. However, there is little information available on the relations among LV size, presence of significant MR, and prognosis in D-HCM patients.We retrospectively studied 31 patients with D-HCM to determine whether echocardiographic assessment of LV size and MR provides incremental prognostic information.During a follow-up period of 5.6 ± 4.2 years, there were 13 cardiovascular deaths. When the patients were divided into two groups by LV size at diagnosis of D-HCM, a non-dilated LV group (LV end-diastolic diameter (LVEDD) < 50 mm, n = 9) and a dilated LV group (LVEDD ≥ 50 mm, n = 22), the clinical course in the non-dilated LV group was significantly worse. As for the clinical impact of MR, no patient in the non-dilated LV group showed significant MR and 7 of the patients with dilated LV size showed significant MR during follow-up. Once significant MR was reached, cardiovascular deaths were significantly more frequent in patients with MR.Patients with D-HCM, particularly those with less LV dilatation at diagnosis of dilated phase and with significant MR during follow-up, have a poor prognosis. (Int Heart J 2017; 58: 63-68)

show abstract

“…A significant proportion (5-10%) of patients with HCM progress to LV systolic impairment due to LV remodeling (so called dilated HCM or end-stage HCM). [26][27][28] To recognize this clinical entity is important because this subgroup of patients develops refractory heart failure and has a poor prognosis. A precise explanation for the relationship between LV systolic impairment and high plasma adiponectin levels in HCM is difficult in our study.…”

Section: Discussionmentioning

confidence: 99%

Plasma Adiponectin Levels and Left Ventricular Remodeling in Hypertrophic Cardiomyopathy

et al. 2010

Self Cite

View full text Add to dashboard Cite

SummaryAdiponectin, which is an adipose-derived protein with antiatherosclerogenic activities, has been reported to be elevated in patients with heart failure. However, there are no reports on the significance of adiponectin in patients with hypertrophic cardiomyopathy (HCM). The purpose of this study was to elucidate the clinical significance of plasma adiponectin levels in HCM patients.Clinical characteristics, echocardiographic parameters, and levels of plasma B-type natriuretic peptide (BNP) and adiponectin were evaluated in 106 HCM patients. The plasma adiponectin levels were 10.8 ± 6.3 (range, 2.7-37.3) μg/mL. Plasma adiponectin levels were positively related to age and inversely related to body mass index (BMI). Among echocardiographic parameters, % fractional shortening (r = -0.20, P = 0.03) and maximum LV wall thickness (r = -0.23, P = 0.02) were inversely related to plasma adiponectin levels. A significant correlation between plasma adiponectin levels and BNP levels was also observed (r = 0.27, P = 0.005). In multivariate analysis, BMI, % fractional shortening, and plasma BNP levels were independent predictors of plasma adiponectin levels.Plasma adiponectin levels are associated with impaired LV systolic function in HCM patients, but not with the LV outflow gradient. Together with BNP, adiponectin can be a useful biomarker for assessing disease severity in HCM patients. (Int Heart J 2010; 51: 51-55) Key words: Hypertrophic cardiomyopathy, Adiponectin, B-type natriuretic peptide, LV remodeling, Heart failure H ypertrophic cardiomyopathy (HCM), a relatively prevalent genetic cardiac disease caused by mutations in genes encoding sarcomere proteins, is clinically defined as left ventricular (LV) hypertrophy with heterogeneous clinical and morphological features in the absence of other cardiovascular diseases.1,2) The clinical and morphological features are diverse and the natural history varies from an asymptomatic and benign clinical course to sudden premature death. [3][4][5] Biomarkers are molecules that are objectively measured by laboratory techniques, which can give us useful information in patients with cardiovascular disease, including HCM. 6) Adipocytokine adiponectin is an adipose-derived protein and shows antiatherosclerogenic and insulin-sensitizing effects. The low plasma levels of adiponectin are associated with type 2 diabetes and ischemic heart disease. [7][8][9][10][11] Moreover, the novel cardiovascular effects of adiponectin have attracted considerable attention in patients with LV hypertrophy and chronic heart failure.12-16) However, the significance of adiponectin has not yet been evaluated in patients with HCM. The purpose of this study was to elucidate the significance of plasma adiponectin levels in HCM. MethodsPatients and study protocol: The study group included 106 patients with HCM diagnosed based on echocardiographic demonstration of a hypertrophied left ventricle (maximum wall thickness ≥ 15 mm) in the absence of systemic hypertension or other cardiac disease that could produc...

show abstract

Left Ventricular Remodeling of Hypertrophic Cardiomyopathy Longitudinal Observation in a Rural Community

Cited by 31 publications

References 34 publications

A985G Polymorphism of the Endothelin-2 Gene and Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

A985G Polymorphism of the Endothelin-2 Gene and Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

Prognostic Significance of Non-Dilated Left Ventricular Size and Mitral Regurgitation in Patients With Dilated Phase of Hypertrophic Cardiomyopathy

Plasma Adiponectin Levels and Left Ventricular Remodeling in Hypertrophic Cardiomyopathy

Contact Info

Product

Resources

About